Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Integra Lifesciences Holdings (IART) Current Taxes (2021 - 2026)

Integra Lifesciences Holdings' Current Taxes history spans 2 years, with the latest figure at $3.7 million for Q4 2025.

On a quarterly basis, Current Taxes changed N/A to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a N/A change, with the full-year FY2025 number at $3.7 million, changed N/A from a year prior.
Current Taxes hit $3.7 million in Q4 2025 for Integra Lifesciences Holdings, down from $24.8 million in the prior quarter.
Over the last five years, Current Taxes for IART hit a ceiling of $24.8 million in Q3 2021 and a floor of $3.7 million in Q4 2025.